RecruitingNCT06205992

3D-MRE and 2D-MRE for Assessing Cirrhosis and Portal Hypertension

Three-dimensional MR Elastography and Two-dimensional MR Elastography for Assessing Cirrhosis and Portal Hypertension：A Prospective Multicenter Study

Sponsor

Shengjing Hospital

Enrollment

100 participants

Start Date

Aug 16, 2022

Study Type

OBSERVATIONAL

Conditions

Cirrhosis Liver Portal Hypertension

Summary

How to construct a novel, non-invasive, accurate, and convenient method to achieve prediction of hepatic venous pressure gradient (HVPG) is an important general problem in the management of portal hypertension in cirrhosis. We plan to compare the ability of three demensional-magnetic resonance elastography (3D-MRE) to two demensional-magnetic resonance elastography (2D-MRE) to establish a risk stratification system and perform tailored management for portal hypertension in cirrhosis.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This study compares two types of MRI-based liver scans — a 3D version and a 2D version — to see which one better measures liver stiffness and blood pressure within the liver in people with cirrhosis. This could help doctors assess liver disease without invasive procedures. **You may be eligible if...** - You are over 18 years old - You have a confirmed diagnosis of cirrhosis - You have had both types of MRI scans within one month before a liver pressure measurement procedure **You may NOT be eligible if...** - You have had previous liver or spleen surgery - You have liver cancer or acute liver failure - You have a pacemaker or metal implants that prevent MRI Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICE3D-MRE

All imaging studies were performed by using a 3.0-T MRI system (Signa HDx, GE Healthcare) with an eight-channel phasedarray body coil.

DEVICEHVPG

HVPG measurements are performed by well-trained interventional radiologists in accordance with standard operating procedures

DEVICE2D-MRE

All imaging studies were performed by using a 3.0-T MRI system (Signa HDx, GE Healthcare) with an eight-channel phasedarray body coil.

DEVICEHVPG

HVPG measurements are performed by well-trained interventional radiologists in accordance with standard operating procedures

Locations(1)

Shengjing Hospital of China Medical University

Shenyang, Liaoning, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06205992

Related Trials

Muscle Mass Via UltraSound in Cirrhosis (MMUSCLE)

NCT063455471 location

PSYLIVER-PILOTE: Involvement of the Autonomic Nervous System in Hepatocellular Carcinoma (HCC)

NCT073930741 location

A Randomized Controlled Study Evaluating Bariatric Surgery as a Treatment for Severe NASH With Advanced Liver Fibrosis in Non-severe Obese Patients

NCT034721571 location

Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI

NCT0548657232 locations

Apixaban-PK Trial: Preventing Portal Hypertension Complications in Cirrhosis

NCT075213321 location